These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 27128212

  • 1. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
    Krishnaswami S, Boy M, Chow V, Chan G.
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
    Lawendy N, Lamba M, Chan G, Wang R, Alvey CW, Krishnaswami S.
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):421-7. PubMed ID: 27129117
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2.
    Klamerus KJ, Alvey C, Li L, Feng B, Wang R, Kaplan I, Shi H, Dowty ME, Krishnaswami S.
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):499-507. PubMed ID: 27129125
    [Abstract] [Full Text] [Related]

  • 5. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
    Mukherjee A, Hazra A, Smith MK, Martin SW, Mould DR, Su C, Niezychowski W.
    Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
    [Abstract] [Full Text] [Related]

  • 6. Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.
    Lamba M, Wang R, Fletcher T, Alvey C, Kushner J, Stock TC.
    J Clin Pharmacol; 2016 Nov; 56(11):1362-1371. PubMed ID: 26970526
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and Bioequivalence of 2 Immediate-Release Tofacitinib Tablet Formulations in Chinese Healthy Volunteers Under Fasting and Fed Conditions.
    Li X, Liu L, Deng Y, Li Y, Zhang P, Wang Y, Xu B, Feng J, Huang L.
    Clin Pharmacol Drug Dev; 2021 May; 10(5):535-541. PubMed ID: 32770665
    [Abstract] [Full Text] [Related]

  • 8. Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
    Miyoshi S, Krishnaswami S, Toyoizumi S, Nakamura H, Zwillich SH.
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):11-20. PubMed ID: 31713350
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
    Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, Papp K.
    Br J Dermatol; 2013 Jul; 169(1):137-45. PubMed ID: 23387374
    [Abstract] [Full Text] [Related]

  • 11. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
    Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R, OPT Pivotal 1 and OPT Pivotal 2 investigators.
    Br J Dermatol; 2015 Oct; 173(4):949-61. PubMed ID: 26149717
    [Abstract] [Full Text] [Related]

  • 12. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
    Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, Wang C, Purohit V, Mamolo C, Papacharalambous J, Ports WC.
    Br J Dermatol; 2016 Nov; 175(5):902-911. PubMed ID: 27423107
    [Abstract] [Full Text] [Related]

  • 13. Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PET.
    Raychaudhuri S, Abria C, Harmany ZT, Smith CM, Kundu-Raychaudhuri S, Raychaudhuri SP, Chaudhari AJ.
    Int J Rheum Dis; 2019 Dec; 22(12):2165-2169. PubMed ID: 31659868
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
    Lomonte ABV, Radominski SC, Marcolino FMD, Brenol CV, Zerbini CAF, García EG, Akylbekova EL, Rojo R, de Leon DP.
    Medicine (Baltimore); 2018 Aug; 97(31):e11609. PubMed ID: 30075534
    [Abstract] [Full Text] [Related]

  • 18. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.
    Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A, Chan GL, Krishnaswami S, Prakash C.
    Drug Metab Dispos; 2014 Apr; 42(4):759-73. PubMed ID: 24464803
    [Abstract] [Full Text] [Related]

  • 19. Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning.
    Purohit VS, Ports WC, Wang C, Riley S.
    J Clin Pharmacol; 2019 Jun; 59(6):811-820. PubMed ID: 30556911
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.